Looking at what Jon Pilcher has said on the matter of plans for NNZ-2591…
During his MST Access presentation mid-last year ((15/06/21) he stressed that NNZ-2591 is Neuren’s “Jewel in the Crown”.
Post-Phase 2, assuming successful results, he said that various options would be looked at for further development, including partnerships in various geographies, or going it alone if Phase 3 trofinetide were successful.
He was adamant that he didn't want to partner US rights of NNZ-2591 at that stage (as happened with trofinetide).
More recently, during the webinar on 7 December 2021, Jon Pilcher reiterated that strategic options would be considered post-Phase 2 NNZ-2591 results, including funding Phase 3, partnering or even selling the company.
He also revealed that he didn’t see the four current indications of NNZ-2591 as the end of possibilities with “numerous others” under consideration. He stated that there would be the chance to look at this more closely in 2022 and advised “watch this space”.
NEU Price at posting:
$3.68 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)